Lifecycle Management

We support our clients in successfully positioning their products and creating value at all phases of the lifecycle: from development to launch, commercialization and beyond.

Pharma companies today need to have a laser focus on defining and delivering value to a diverse set of stakeholders, starting at discovery through to commercialization and end-of-exclusivity. The successful companies are the ones that put customers (payers, healthcare professionals, patients) at the heart of the value delivery process and deliver flawlessly across all functions across the whole lifecycle. Executive Insight supports leading biopharmaceutical companies in the key phases:

• Shape value early on
  Integrating commercial and customer insights earlier into the new product process is key as a basis for early-stage decision making, for targeting promising compounds, and for increasing the potential to launch a successful drug. 
We support early-stage commercialization activities for example through therapeutic opportunity and competitive landscape assessments, through integrating the policy, payer, HCP and patient perspective and through strategic definition of value and positioning to guide the development process.
• Maximize launch success
  A successful product launch in today’s competitive and regulated marketplace is highly dependent on value-based and science-driven decision making. Tightening constraints, especially on market access, are creating an increasingly tough launch environment. Success involves a thorough understanding what constitutes value for payers, HCPs and patients and finding a strong and relevant positioning to successfully differentiate and deliver on customer expectations.
We support clients in carving out clear a positioning, exploring and implementing beyond-the-pill strategies and shaping and communicating compelling value stories that resonate with payers, HCPs and patients. 
• Boost brand and franchise performance
  In today’s highly competitive markets there is fierce competition, especially also from generics and biosimilars. To maximize the business opportunity in this stage there is a need to plan early, develop more comprehensive lifecycle management strategies and to continue to differentiate e.g. through product enhancements and services.
We support our clients in this phase for example through defining contracting strategies, a strategic approach to tender shaping or defining and implementing biosimilar defense strategies.